Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus XYLOCAINE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus XYLOCAINE W EPINEPHRINE.
LABETALOL HYDROCHLORIDE vs XYLOCAINE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
Lidocaine blocks voltage-gated sodium channels, inhibiting neuronal depolarization and conduction. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor agonism, reducing systemic absorption and prolonging local anesthetic action.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
Adults: 1-5 mL of 1% or 2% solution (maximum 7 mg/kg lidocaine without epinephrine; 7 mg/kg with epinephrine; not to exceed 500 mg total) by infiltration or nerve block, not to be repeated within 2 hours.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Lidocaine terminal half-life: ~1.5-2 hours (initial); ~2-4 hours (terminal) after IV. Prolonged in hepatic dysfunction (up to 5-7 hours) and congestive heart failure (up to 10 hours).
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Renal: lidocaine and metabolites (primarily 4-hydroxyxylidine and glycinexylidide) ~90% as metabolites, <10% unchanged. Biliary/fecal: minor (approximately 3-5%).
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist